<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494467</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18171</org_study_id>
    <nct_id>NCT01494467</nct_id>
  </id_info>
  <brief_title>Phase 3 Papulopustular Rosacea Study</brief_title>
  <official_title>A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its
      vehicle when applied once daily, at bed time, during a 12 week period in subjects with
      Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects who achieve &quot;Clear&quot; (Score 0) or &quot;Almost Clear&quot; (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.
Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:
Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change in Inflammatory Lesion Count</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">688</enrollment>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>CD5024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD5024 1% Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD5024 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CD5024 Vehicle Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD5024</intervention_name>
    <description>CD5024 1% Cream, once daily</description>
    <arm_group_label>CD5024</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid 15% Gel</intervention_name>
    <description>Topical Gel applied twice daily</description>
    <arm_group_label>CD5024 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA)
             score rated 3 (moderate) or 4 (severe),

          2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and
             pustules) on the face.

        Exclusion Criteria:

          1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans,
             isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that
             may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial
             keratosis pilaris, seborrheic dermatitis, and acne,

          2. The subject has rosacea with more than two nodules on the face.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin and Beauty</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobil</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists, Inc</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group, Inc</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATS Clinical Research</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Dermatology Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Corp Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leavitt Medical Associates of Florida dba Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center, LLC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Dermatology Associates</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Fivenson, MD, PLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Trials Unit</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of NJ</name>
      <address>
        <city>West Windsor</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Center of New York, Inc</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Surgery Center</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Institute of Dermatology</name>
      <address>
        <city>Fort Washington</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yardley Dermatology Associates</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Reserach Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>17203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Miller MD</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guildford Dermatology Specialists</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Guenther Dermatology Research Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre, Inc</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology &amp; Cosmetic Surgery</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 Medical Research, Inc</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec Metropolitan</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <results_first_submitted>January 8, 2015</results_first_submitted>
  <results_first_submitted_qc>January 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <disposition_first_submitted>January 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 28, 2014</disposition_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD5024 1% Cream</title>
          <description>Part A &amp; B: CD5024 1% Cream, once daily application</description>
        </group>
        <group group_id="P2">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel</title>
          <description>Part A: CD5024 Vehicle Cream, once daily application
Part B: Azelaic acid 15% Gel, twice daily application</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A Vehicle Control (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="459"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B Long Term Active Control 40 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="428">429 completed Part A. Subsequently, one subject discontinued so only 428 entered Part B</participants>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (noted in eCRF)</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C Safety Follow up (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>CD5024 1% Cream</title>
          <description>Part A: CD5024 1% Cream, once daily application for 12 weeks
Part B: CD5024 1% Cream, once daily application for 40 weeks</description>
        </group>
        <group group_id="B2">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel</title>
          <description>Part A: CD5024 Vehicle Cream, once daily application for 12 weeks
Part B: Azelaic acid 15% Gel, twice daily application for 40 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="459"/>
            <count group_id="B2" value="229"/>
            <count group_id="B3" value="688"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="12.35"/>
                    <measurement group_id="B2" value="49.5" spread="12.16"/>
                    <measurement group_id="B3" value="50.2" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="438"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Photo Type</title>
          <description>DEFINITION OF SKIN PHOTOTYPE (T.B. Fitzpatrick):
I: Always burns easily ; never tans II: Always burns easily ; tans minimally and with difficulty III: Burns minimally ; tans gradually and uniformly (light Brown) IV: Burns minimally ; always tans well (moderate brown) V: Rarely burns ; tans profusely (dark brown)) VI:Never burns ; deeply pigmented (black), tans profusely</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate</title>
        <description>Percentage of subjects who achieve &quot;Clear&quot; (Score 0) or &quot;Almost Clear&quot; (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.
Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:
Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)</description>
        <time_frame>Week 12</time_frame>
        <population>LOCF, ITT</population>
        <group_list>
          <group group_id="O1">
            <title>CD5024 1% Cream</title>
            <description>CD5024 1% Cream, once daily application for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CD5024 Vehicle Cream</title>
            <description>CD5024 Vehicle Cream, once daily application for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate</title>
          <description>Percentage of subjects who achieve &quot;Clear&quot; (Score 0) or &quot;Almost Clear&quot; (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.
Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:
Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)</description>
          <population>LOCF, ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Inflammatory Lesion Count</title>
        <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>LOCF, ITT</population>
        <group_list>
          <group group_id="O1">
            <title>CD5024 1% Cream</title>
            <description>CD5024 1% Cream, once daily application for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CD5024 Vehicle Cream</title>
            <description>CD5024 Vehicle Cream, once daily application for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Lesion Count</title>
          <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
          <population>LOCF, ITT</population>
          <units>Lesion count change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" spread="14.87"/>
                    <measurement group_id="O2" value="-13.4" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.18</ci_lower_limit>
            <ci_upper_limit>-6.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)</title>
        <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CD5024 1% Cream</title>
            <description>CD5024 1% Cream, once daily application for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CD5024 Vehicle Cream</title>
            <description>CD5024 Vehicle Cream, once daily application for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)</title>
          <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
          <units>Percentage of change in lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.7" spread="33.18"/>
                    <measurement group_id="O2" value="-43.4" spread="38.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of signed informed consent to study end (~ 58 wks). Treatment emergent adverse events - occurred on date of 1st use of medication or after, except those reported from Day 1 lab data as blood sample was to be drawn before the time of 1st dose.</time_frame>
      <desc>Number of participants at risk based on actual number of participants who received each intervention as randomized or due to dispensing errors (3 subjects).</desc>
      <group_list>
        <group group_id="E1">
          <title>CD5024 1% Cream - Part A</title>
          <description>Part A: CD5024 1% Cream, once daily application for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>CD5024 Vehicle Cream - Part A</title>
          <description>Part A: CD5024 Vehicle Cream, once daily application for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>CD5024 1% Cream - Part B</title>
          <description>Part B CD5024 1% Cream, once daily application for 40 weeks</description>
        </group>
        <group group_id="E4">
          <title>Azelaic Acid 15% Gel - Part B</title>
          <description>Part B: Subjects in the CD5024 Vehicle Cream arm applied Azelaic Acid 15% Gel twice daily for 40 weeks</description>
        </group>
        <group group_id="E5">
          <title>CD5024 1% Cream - Part C</title>
          <description>Part C: 4 week safety follow up. No drug applications</description>
        </group>
        <group group_id="E6">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C</title>
          <description>Part C: 4 week safety follow up. No drug applications</description>
        </group>
        <group group_id="E7">
          <title>CD5024 1% Cream - Overall</title>
          <description>Overall number of subjects with adverse events for the entire duration of study</description>
        </group>
        <group group_id="E8">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall</title>
          <description>Overall number of subjects with adverse events for the entire duration of study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="125" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="64" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="52" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="48" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="428"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="460"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least sixty (60) days prior to submission for publication, presentation or use, the Institution and the Investigator shall submit in writing to the Contract Research Organization and Sponsor for review and comment any proposed oral or written publication, which period may be extended for an additional thirty (30) days if requested in writing by Contract Research Organization and Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Science Director</name_or_title>
      <organization>Galderma R&amp;D, LLC</organization>
      <phone>609-409-7701</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

